Other targets being treated with investigational mAbs in PTCL include TNF receptor 2 (TNFR2), a signaling molecule found on the surface of regulatory T-cells that mediates proinflammatory responses [35]; the inducible T-cell costimulator (ICOS), which is highly expressed by T-follicular helper cells (TFHs) [36]; and the killer cell immunoglobulin-like receptor (three domains) long cytoplasmic tail 2 (KIR3DL2) to improve NK cell recruitment and ADCC [37]. Here, ICOS is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.